Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, on the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker.
Emmanuel S. Antonarakis, MBBCh, associate professor, Johns Hopkins Medicine, discusses the coming importance of being tested for the ARV7 marker and future treatments for patients with the marker. Antonarakis says in the future, the ARV7 marker could be an indicator for certain treatments like an androgen receptor therapy, such as enzalutamide or abiraterone, or a chemotherapy like docetaxel or cabazitaxel.
Antonarakis adds that it is only a matter of time before phase II and phase III trials will be available for oncologists to put patients on, specifically patients who express ARV7.
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen